Proton magnetic resonance spectroscopy changes in a longitudinal schizophrenia study: a pilot study in eleven patients

References

• LiebermanJAIs schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspectiveBiol Psychiatry199946672973910494440
   PubMed Web of Science ®Google Scholar
• WeinbergerDRImplications of normal brain development for the pathogenesis of schizophreniaArch Gen Psychiatry19874476606693606332
   PubMed Web of Science ®Google Scholar
• WoodsBTIs schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenic mechanismAm J Psychiatry1998155121661167010.1176/ajp.155.12.16619842773
   PubMed Web of Science ®Google Scholar
• DagerSROskinNMRichardsTLPosseSResearch applications of magnetic resonance spectroscopy (MRS) to investigate psychiatric disordersTop Magn Reson Imaging2008192819610.1097/RMR.0b013e318181e0be19363431
   PubMedGoogle Scholar
• DemougeotCMarieCGiroudMBeleyAN-acetylaspartate: a literature review of animal research on brain ischaemiaJ Neurochem200490477678310.1111/j.1471-4159.2004.02583.x15287882
   PubMed Web of Science ®Google Scholar
• Galińska-SkokBMałusAKonarzewskaBCholine compounds of the frontal lobe and temporal glutamatergic system in bipolar and schizophrenia proton magnetic resonance spectroscopy studyDis Markers201810.1155/2018/3654894
   Web of Science ®Google Scholar
• WaszkiewiczNGalińska-SkokBNestsiarovichANeurobiological effects of binge drinking help in its detection and differential diagnosis from alcohol dependenceDis Markers201810.1155/2018/5623683
   Web of Science ®Google Scholar
• IwataYNakajimaSPlitmanEMihashiYCaravaggioFChungJKNeurometabolite levels in antipsychotic-naïve/free patients with schizophrenia: a systematic review and meta-analysis of 1H-MRS studiesProg Neuropsychopharmacol Biol Psychiatry2018308634035210.1016/j.pnpbp.2018.03.016
   Web of Science ®Google Scholar
• MolinaVSánchezJReigSN-acetyl-apartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease durationSchizophr Res2005732–320921910.1016/j.schres.2004.02.00115653263
   PubMed Web of Science ®Google Scholar
• AoyamaNThébergeJDrostDJGrey matter and social functioning correlates of glutamatergic metabolite loss in schizophreniaBr J Psychiatry2011198644845610.1192/bjp.bp.110.07960821628707
   PubMed Web of Science ®Google Scholar
• ThébergeJWilliamsonKEAoyamaNLongitudinal grey-matter and glutamatergic losses in first-episode schizophreniaBr J Psychiatry200719132533410.1192/bjp.bp.106.03367017906243
   PubMed Web of Science ®Google Scholar
• BustilloJRRowlandLMJungRProton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophreniaNeuropsychopharmacology200833102456246610.1038/sj.npp.130163118094668
   PubMed Web of Science ®Google Scholar
• GalińskaBSzulcATarasówERelationship between frontal N-acetylaspartate and cognitive deficits in first-episode schizophreniaMed Sci Monit200713Suppl 1111617507879
   PubMedGoogle Scholar
• WoodsSWChlorpromazine equivalent doses for the newer atypical antipsychoticsJ Clin Psychiatry200364666366712823080
   PubMed Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe Positive and Negative Syndrome Scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
   PubMed Web of Science ®Google Scholar
• AddingtonDAddingtonJMaticka-TyndaleEAssessing depression in schizophrenia: The Calgary Depression ScaleBr J Psychiatry Suppl199322394410.1192/S0007125000292581
   Google Scholar
• GuyWECDEU Assessment Manual for PsychopharmacologyWashington, DCUS Department of Health, Education, and Welfare1976
   Google Scholar
• GalińskaBSzulcATarasówEDuration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophreniaMed Sci Monit200915CR8288
   Google Scholar
• MurdochJBLampmanDABeyond Wet and Dry: Optimized Pulses for Water Suppression. Society of Magnetic Resonance in MedicineNew YorkTwelfth Annual Meeting19931191
   Google Scholar
• HeatonRKCheluneGJTalleyJLKayGGCurtissGWisconsin Card Sorting Test Manual Revised and ExpandedOdessa (FL)Psychological Assessment Resources1993
   Google Scholar
• HeatonRKWisconsin Card Sorting Test: Computer Version 2 Research EditionOdessa (FL)Psychological Assessment Resources19901993
   Google Scholar
• BustilloJRLaurielloJRowlandLMLongitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposureSchizophr Res2002582–331332112409172
   PubMed Web of Science ®Google Scholar
• FannonDSimmonsATennakoonLSelective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophreniaBiol Psychiatry200354658759813129653
   PubMed Web of Science ®Google Scholar
• WoodSJBergerGEWellardRMA 1H MRS investigation of the medial temporal lobe in antipsychotic-naïve early-treated first episode psychosisSchizophr Res20081021–316317010.1016/j.schres.2008.03.01218456460
   PubMed Web of Science ®Google Scholar
• GrošićVGrošićPFKalemberPThe effect of atypical anti-psychotics on brain N-acetylaspartate levels in antipsychotic-naïve first-episode patients with schizophrenia: a preliminary studyNeuropsychiatr Dis Treat2014101243125310.2147/NDT.S6141525045268
   PubMed Web of Science ®Google Scholar
• BertolinoACallicottJHMattayVSThe effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophreniaBiol Psychiatry2001491394611163778
   PubMed Web of Science ®Google Scholar
• SzulcAGalińska-SkokBWaszkiewiczNProton magnetic resonance spectroscopy changes after antipsychotic treatmentCurr Med Chem201320341442723157634
   PubMed Web of Science ®Google Scholar
• ChoeBYSuhTSShinKSLeeCWLeeCPaikIHObservation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopyInvest Radiol19963163453528761867
   PubMed Web of Science ®Google Scholar
• SzulcAGalińskaBTarasówEThe effect of risperidone on metabolite measures in the frontal lobe, temporal lobe and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS) studyPharmacopsychiatry200538521421910.1055/s-2005-87315616189748
   PubMed Web of Science ®Google Scholar
• ErtrugrulAVolkan-SalanciBKorayBThe effect of clozapine on regional cerebral blood flow and brain metabolite ratios in schizophrenia: relationship with treatment responsePsychiatry Res2009174212112910.1016/j.pscychresns.2009.04.00719837567
   PubMed Web of Science ®Google Scholar
• SzulcAGalińskaBTarasówEN-acetylaspartate (NAA) levels in selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics: a proton magnetic resonance spectroscopy (1H MRS) studyMed Sci Monit200713Suppl 1172217507880
   PubMedGoogle Scholar
• BustilloJRRowlandLMMullinsP1H MRS at 4 Tesla in minimally treated early schizophreniaMol Psychiatry201015662963610.1038/mp.2009.12119918243
   PubMed Web of Science ®Google Scholar
• MaddockRJBuonocoreMHMR spectroscopic studies of the brain in psychiatric disordersCurr Top Behav Neurosci20121119925122294088
   PubMedGoogle Scholar
• RowlandLMDemyanovichHKWijtenburgSAEatonWWRodriguezKGastonFAntigliadin antibodies (AGA IgG) are related to neurochemistry in schizophreniaFront Psychiatry2017810410.3389/fpsyt.2017.0029728674504
   PubMed Web of Science ®Google Scholar
• ChangLFriedmanJErnstTZhongKTsopelasDDavisKBrain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunctionBiol Psychiatry200762121396140410.1016/j.biopsych.2007.05.02517693392
   PubMed Web of Science ®Google Scholar
• GoldSArndtSNopoulosPO’LearyDSAndreasenNCLongitudinal study of cognitive function in first-episode and recent-onset schizophreniaAm J Psychiatry199915691342134810.1176/ajp.156.9.134210484943
   PubMed Web of Science ®Google Scholar
• AddingtonJSaeediHAddingtonDThe course of cognitive functioning in first episode psychosis: changes over time and impact on outcomeSchizophr Res2005781354310.1016/j.schres.2005.05.00815978781
   PubMed Web of Science ®Google Scholar
• HoffALSvetinaCShieldsGStewartJDeLisiLETen year longitudinal study of neuropsychological functioning subsequent to first episode of schizophreniaSchizophr Res2005781273410.1016/j.schres.2005.05.01015964177
   PubMed Web of Science ®Google Scholar
• StirlingJWhiteCLewisSNeurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of epidemiological cohortSchizophr Res2003652–3758614630300
   PubMed Web of Science ®Google Scholar
• OrellanaGSlachevskyAExecutive functioning in schizophreniaFront Psychiatry201343510.3389/fpsyt.2013.0003523805107
   PubMedGoogle Scholar
• KandratsenkaHNestsiarovichAGoloenkoIAssociation of mir137 with symptom severity and cognitive functioning in belarusian schizophrenia patientsFront Psychiatry2018929510.3389/fpsyt.2018.0029530026708
   PubMed Web of Science ®Google Scholar
• VenkatramanTNHamerRMPerkinsDOSongAWLiebermanJASteenRGSingle-voxel 1H PRESS at 4.0 T: precision and variability of measurements in anterior cingulated and hippocampusNMR Biomed200619448449110.1002/nbm.105516763968
   PubMed Web of Science ®Google Scholar
• AuerDPWilkeMGrabnerAHeidenreichJOBronischTWetterTCReduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentationSchizophr Res2001521–2879911595395
   PubMed Web of Science ®Google Scholar